FOLD News and Press, Amicus Therapeutics Inc. From 06/19/23

2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...

2023-05-22 16:25:38 ET Summary The FDA inspected the WuXi facility this month, and Amicus Therapeutics, Inc. expects approval in the third quarter. Galafold revenue is growing, although the ANDA challenge needs to be resolved. I expect the next 3-4 months to be very exciting. ...

2023-05-10 12:03:09 ET Amicus Therapeutics Inc. (FOLD) Q1 2023 Earnings Conference Call May 10, 2023 8:30 am ET Company Participants Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Develop...

2023-05-10 07:04:12 ET Amicus Therapeutics press release ( NASDAQ: FOLD ): Q1 GAAP EPS of -$0.18 misses by $0.03 . Revenue of $86.27M (+9.6% Y/Y) beats by $3.06M . FY2023 Outlook : The company anticipates total Galafold revenue growth between 12 and 17% at ...

1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Complete; Approval Expected 3Q 2023 European Launch of Pombiliti ® +O...

2023-05-09 12:12:31 ET Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.14 (+53.3% Y/Y) and the consensus Revenue Estimate is $83.21M (+5.7% Y/Y). Over the la...

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care Conference in Las Vegas, NV on Thursday, May 11, 2023, at 8:40 a.m. PT. A live audio webcast of the p...

PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023. Particip...

2023-04-28 05:30:40 ET A committee of the European Medicines Agency (EMA) recommended the approval of Amicus Therapeutics' ( NASDAQ: FOLD ) oral therapy Opfolda (miglustat) in combination with cipaglucosidase alfa to treat glycogen storage disease type 2, or Pompe disease....

European Commission Approval of Opfolda and Commercial Launch of Pombiliti ® + Opfolda ® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adu...